List of Excipients in Branded Drug CLEARLAX

Generic Drugs Containing CLEARLAX

Company	Ingredient	NDC	Excipient
Wal-Mart Stores Inc	polyethylene glycol 3350	49035-316	SODIUM HYDROXIDE
H E B	polyethylene glycol 3350	59640-797	SUCRALOSE
Meijer Inc	polyethylene glycol 3350	79481-0090	SUCRALOSE

What are the Most Frequently-Used Excipients in CLEARLAX?

# Of NDCs	Excipient
1	SODIUM HYDROXIDE
2	SUCRALOSE

ClearLax Excipient Strategy and Commercial Opportunities for Polyethylene Glycol 3350

Last updated: August 20, 2026

ClearLax is a U.S. over-the-counter osmotic laxative containing 17 grams of polyethylene glycol 3350, or PEG 3350, per dose. Its current commercial strategy is unusually lean: the product is an unflavored powder for oral solution and the U.S. Drug Facts label identifies no inactive ingredients. The principal opportunities are packaging, convenience, flavor, pediatric positioning, private-label expansion, and international registration rather than new active-ingredient patents.

What is ClearLax and how is it regulated?

ClearLax is a PEG 3350 powder used for occasional constipation. The labeled adult dose is 17 grams dissolved in 4 to 8 ounces of beverage and taken once daily. The product is generally labeled for adults and children aged 17 years and older, with younger patients directed to consult a physician [1].

Product attribute	ClearLax position
Active ingredient	Polyethylene glycol 3350
Dose	17 g per dose
Dosage form	Powder for oral solution
Route	Oral
Therapeutic category	Osmotic laxative
Flavor profile	Unflavored
Labeled population	Adults and children 17 years and older
Typical administration	Dissolve in 4 to 8 oz of beverage
U.S. regulatory route	OTC laxative framework
Orange Book status	No conventional Orange Book listing identified for the private-label OTC product
Biosimilar exposure	None
Primary competition	MiraLAX, generic PEG 3350, store brands, stimulant laxatives, fiber products

PEG 3350 is a high-molecular-weight, nonabsorbable polymer that retains water in the stool. It is pharmacologically distinct from stimulant laxatives such as bisacodyl and senna, and from bulk-forming products such as psyllium.

What excipients are used in ClearLax?

ClearLax uses an excipient-minimization strategy. The current product labeling identifies no inactive ingredients, meaning the formulation is effectively PEG 3350 alone in a powder presentation [1].

This approach reduces several technical and commercial risks:

• Lower risk of excipient-related intolerance.
• No sweetener or flavor declaration.
• Fewer raw-material suppliers.
• Simplified analytical testing.
• Lower formulation complexity.
• Reduced risk of incompatibility with beverages.
• Easier private-label manufacturing and packaging.

PEG 3350 is the active ingredient, not an excipient. The formulation therefore does not rely on a conventional carrier, binder, coating agent, flavor system, preservative, or tableting aid.

Why does an excipient-free formulation matter commercially?

An excipient-free formulation can support a clean-label position and reduce cost of goods. It also allows the manufacturer to describe the product as unflavored and free of added inactive ingredients, subject to the exact wording permitted by applicable labeling rules.

The tradeoff is user experience. Unflavored PEG 3350 dissolves in a wide range of beverages, but the absence of flavoring does not eliminate the possibility of texture, mouthfeel, or mild taste perception. Consumers must also measure a 17-gram dose unless the package includes a suitable measuring device.

The product’s simplicity can therefore be an advantage in pharmacy and mass retail, while leaving room for competitors to differentiate on convenience rather than pharmacology.

What formulation patents protect ClearLax?

No material product-specific formulation patent estate is apparent for the standard ClearLax PEG 3350 powder presentation. PEG 3350 is a long-established pharmaceutical ingredient, and the basic concept of dissolving 17 grams in a beverage is unlikely to create meaningful composition-of-matter exclusivity.

The main intellectual-property assets are more likely to be:

1. The ClearLax trademark and related brand identifiers.
2. Packaging design and trade dress.
3. Supplier and manufacturing know-how.
4. Quality specifications for PEG 3350.
5. Distribution agreements and retailer placement.
6. Potential future patents covering improved delivery systems or differentiated formulations.

A new formulation would need a technical distinction capable of supporting patentability. Examples could include a stable flavored powder, a rapidly dispersing stick pack, a unit-dose system with improved dose accuracy, or a formulation designed to reduce perceived mouthfeel. A basic flavor addition or ordinary packaging change would face a higher obviousness risk.

Does ClearLax have Orange Book or Paragraph IV exposure?

ClearLax does not have the same Orange Book profile as a prescription NDA product. The product is marketed as an OTC drug under the applicable nonprescription laxative framework, not as a conventional prescription product that depends on an innovator NDA listing for commercial protection [2].

As a result:

• A conventional Orange Book patent certification analysis is generally not the central entry issue.
• Paragraph IV litigation is not the expected pathway for challenging a standard OTC monograph product.
• Generic manufacturers can compete through OTC monograph compliance and their own labeling and manufacturing systems.
• The central barriers are regulatory compliance, supply, quality, retail access, and brand economics.

PEG 3350 products are often described commercially as “generic” because they compete with branded and store-brand products on an equivalent active ingredient and dosage form. The legal pathway is more accurately analyzed as OTC monograph or OTC drug compliance rather than an abbreviated new drug application challenge to a listed prescription product.

When does ClearLax lose exclusivity?

ClearLax has no meaningful active-ingredient exclusivity period. PEG 3350 is an established ingredient, and competing PEG 3350 products are already available in the U.S. market.

Exclusivity category	ClearLax position
New chemical entity exclusivity	None
Orphan-drug exclusivity	None
Biologic exclusivity	None
Pediatric exclusivity	None identified
Prescription NDA exclusivity	Not the relevant commercial framework
Patent-based active-ingredient exclusivity	None of practical significance
Brand protection	Trademark, packaging, retailer control, and consumer recognition
Market protection	Retail distribution, price, availability, and brand trust

ClearLax can lose share without a patent expiry event. Retailers can substitute another PEG 3350 product quickly, particularly when the product is sold under a private-label model.

What commercial opportunities exist for ClearLax excipients and delivery systems?

Single-dose stick packs

Single-dose sachets are the most direct opportunity. They can provide:

• More accurate dosing than a household spoon.
• Improved portability.
• Better use in travel, workplaces, and assisted-care settings.
• Lower contamination risk after opening.
• Easier pharmacy and e-commerce merchandising.

A stick-pack version could contain 17 grams of PEG 3350 with no excipients, preserving the current clean-label strategy. The packaging must control moisture uptake because PEG powders can be hygroscopic and may experience caking or flow changes under poor storage conditions.

Flavored PEG 3350 powders

Flavoring could address the main consumer-experience limitation of an unflavored powder. Candidate profiles could include citrus, berry, or neutral sweetened systems. The formulation would need to control:

• Flavor stability over shelf life.
• Sweetener compatibility.
• Moisture sensitivity.
• Beverage dispersion.
• Color stability.
• Residual taste.
• Consumer perception of artificial ingredients.

A flavored product would expand consumer choice but would lose the simplicity of the “no inactive ingredients” position. It could be marketed as a separate premium SKU rather than replacing the unflavored product.

Dose-measuring systems

A calibrated scoop, cup, or premeasured packet could create a practical advantage without changing the active formulation. Dose accuracy is commercially relevant because the label uses a weight-based 17-gram dose while consumers may measure powder volumetrically.

Potential improvements include:

• A fixed-volume scoop validated to deliver 17 grams within a defined tolerance.
• A level-fill scoop with a dose bridge or fill line.
• A package with premeasured daily doses.
• A child-resistant multi-dose container paired with a dose cup.

The dose-delivery system may be more commercially defensible than a basic excipient change, although patentability would depend on the specific structure and technical effect.

Rapid-dispersing formulations

A rapidly dispersing PEG 3350 powder could improve consumer convenience. Possible approaches include particle-size engineering, granulation, or a low-moisture agglomerated powder. These approaches may improve wetting and dispersion but can introduce manufacturing and stability issues.

The technical target should be measurable. Relevant performance metrics include:

• Time to disperse in a specified beverage volume.
• Residual undissolved material.
• Caking after accelerated storage.
• Dose uniformity.
• Flowability.
• Bulk density.
• Moisture content.

A formulation that disperses faster without materially changing the PEG 3350 dose could support a differentiated product claim if the claim is substantiated and permitted by FDA labeling rules.

What pediatric opportunities exist for PEG 3350 products?

ClearLax labeling does not position the product for routine self-treatment in children younger than 17 years [1]. A pediatric opportunity would therefore require a separate regulatory, clinical, and labeling strategy rather than a simple package redesign.

Potential pediatric products could use:

• Lower unit doses.
• Premeasured sachets.
• Child-acceptable flavor systems.
• Smaller beverage volumes.
• Caregiver-focused dosing instructions.
• Packaging designed to reduce dosing errors.

The commercial opportunity is substantial because constipation treatment in children depends heavily on caregiver usability and dose control. The regulatory burden is higher because pediatric dosing, safety, labeling, and claims require support beyond the standard adult OTC presentation. A children’s product could be positioned as a separate SKU, but it should not rely solely on reducing the amount of PEG 3350 in the existing adult package.

How does ClearLax compare with MiraLAX and generic PEG 3350?

Factor	ClearLax	MiraLAX	Other PEG 3350 store brands
Active ingredient	PEG 3350	PEG 3350	PEG 3350
Standard dose	17 g	17 g	Usually 17 g
Dosage form	Powder for solution	Powder for solution	Powder for solution
Flavor	Generally unflavored	Generally unflavored	Unflavored or product-specific
Inactive ingredients	Label identifies none	Product-specific labeling	Product-specific labeling
Primary advantage	Private-label price and retailer access	Brand recognition and consumer awareness	Price and availability
Patent moat	Limited	Limited for standard PEG powder	Limited
Main differentiation	Retail execution and price	Brand trust and marketing	Cost and channel placement

MiraLAX has stronger consumer recognition, while ClearLax can compete through retail pricing and store-brand economics. The product category is vulnerable to substitution because the active ingredient, dose, and administration method are familiar to consumers.

What manufacturing and intellectual-property barriers affect ClearLax?

The principal manufacturing barriers are operational rather than patent-based.

PEG 3350 supply

A manufacturer needs reliable pharmaceutical-grade PEG 3350 with controlled molecular-weight distribution, impurity profile, moisture level, and microbiological quality. Supplier qualification and continuity are important because a raw-material disruption can affect multiple private-label SKUs simultaneously.

Powder handling

Manufacturing controls must address:

• Segregation and blend uniformity, where applicable.
• Dust management.
• Powder flow.
• Static buildup.
• Moisture ingress.
• Container-closure integrity.
• Fill-weight accuracy.
• Cleaning validation.

Packaging

Multi-dose bottles are economical but expose the powder to repeated opening and closing. Single-dose sachets improve convenience and dose control but raise packaging-material and filling costs.

Packaging development should evaluate:

• High-barrier films.
• Heat-seal performance.
• Desiccant requirements.
• Child-resistant features.
• Tamper evidence.
• Shipping durability.
• Powder retention in the sachet.

The IP barrier is low for a conventional bottle or sachet. Stronger patent positions would require a specific technical architecture, such as a novel dose-delivery mechanism, moisture-control package, or formulation with demonstrated performance benefits.

What patent litigation or settlement risk affects ClearLax?

No major patent litigation risk is expected for a standard PEG 3350 OTC powder. The product does not depend on a narrow prescription patent estate, and generic or private-label competition is already established.

Future disputes are more likely to involve:

• Trademark infringement.
• Packaging and trade-dress similarity.
• Retailer or distributor agreements.
• Advertising claims.
• Pediatric or faster-dispersing formulation patents.
• Manufacturing know-how and supplier confidentiality.

Settlement agreements involving prescription competitors are unlikely to determine ClearLax market access. Any settlement related to a new proprietary delivery system would be product-specific and would not necessarily restrict ordinary PEG 3350 powder competition.

What geographic expansion opportunities exist?

ClearLax is primarily a U.S. retail opportunity under its current brand and regulatory positioning. International expansion would require country-specific assessment of:

• Whether PEG 3350 is classified as a drug, medicine, medical product, or supplement.
• Permitted constipation claims.
• Pediatric labeling requirements.
• Pharmacopoeial standards.
• Import and local manufacturing rules.
• Language and packaging requirements.
• Maximum daily dose and treatment-duration rules.

The simplest expansion model is private-label supply of PEG 3350 powder to national pharmacy chains and e-commerce retailers. A branded international launch would require stronger consumer differentiation because PEG 3350 products compete largely on price, availability, and dosing convenience.

How strong is the ClearLax patent estate?

The patent estate is weak for the conventional product but commercially adequate for a private-label OTC medicine.

Asset	Strategic strength
PEG 3350 composition	Very low exclusivity value
Standard 17-gram powder	Low
Conventional bottle packaging	Low
Trademark	Moderate, depending on registration and use
Retailer placement	Moderate to strong in the relevant channel
Supplier relationships	Moderate
Flavored formulation	Potentially moderate if technically differentiated
Pediatric delivery system	Potentially moderate to strong with supporting data
Moisture-resistant unit-dose package	Potentially moderate
Consumer brand recognition	Dependent on marketing and retailer investment

The commercial moat is based on execution, not exclusivity. A new entrant can generally compete by sourcing compliant PEG 3350, obtaining an OTC-compliant label, qualifying a contract manufacturer, and securing retail distribution.

What revenue exposure and generic launch scenarios exist?

ClearLax-specific revenue is not separately disclosed in public corporate reporting. The product is likely exposed to the economics of private-label OTC medicines, where volume and retailer relationships matter more than premium pricing.

Three launch scenarios are commercially relevant:

1. Price-led private-label entry. A competing retailer launches an equivalent 17-gram PEG 3350 powder at a lower price. This is the highest-probability threat.
2. Convenience-led entry. A competitor introduces unit-dose sachets, improved dose measurement, or faster dispersion.
3. Experience-led entry. A competitor introduces a flavored or pediatric product with stronger consumer acceptance.

ClearLax can defend share through stable supply, lower pricing, retailer exclusivity, improved packaging, and selective line extensions. The strongest near-term opportunity is a premeasured, moisture-protected stick pack that retains the no-added-excipient formulation.

Key Takeaways

• ClearLax contains 17 grams of PEG 3350 and is marketed as an unflavored powder for oral solution.
• The current label identifies no inactive ingredients, giving the product a low-complexity, clean-label formulation.
• Standard ClearLax has little practical patent protection and no meaningful active-ingredient exclusivity.
• Paragraph IV litigation and Orange Book patent challenges are not the primary market-entry issues.
• The main competitive risks are lower-priced store brands, retailer substitution, and convenience-focused products.
• The strongest commercial extensions are single-dose sachets, validated dose-measuring systems, flavored powders, and pediatric-specific presentations.
• Pediatric products and novel delivery systems would require separate regulatory and technical support.
• Manufacturing barriers center on PEG 3350 quality, powder flow, moisture control, dose uniformity, and packaging integrity.
• Brand, trademark, trade dress, retail access, and supply reliability are more important than patent exclusivity for the current product.

FAQs

Is ClearLax the same as MiraLAX?

Both products use PEG 3350 as the active ingredient and commonly provide a 17-gram dose. Differences can arise in labeling, packaging, inactive ingredients, quality specifications, price, and retailer positioning.

Can ClearLax be reformulated as a gummy?

A gummy would be a materially different dosage form requiring a new formulation, stability program, manufacturing process, dose-delivery assessment, and regulatory review. PEG 3350’s high dose makes a gummy presentation technically less efficient than a powder or sachet.

Can a company patent a flavored PEG 3350 product?

A flavor addition alone may provide limited patent protection. A stronger patent position would require a specific formulation, stability advantage, sensory result, dispersion benefit, or delivery architecture that is novel and non-obvious.

Is PEG 3350 suitable for a combination laxative product?

PEG 3350 could be combined with another laxative or supportive ingredient, but the combination would require compatibility testing, dose justification, labeling review, and assessment under the applicable OTC regulatory framework.

What is the best premium product concept for ClearLax?

A premeasured 17-gram stick pack with moisture-resistant packaging, accurate dose delivery, rapid dispersion, and optional flavor variants offers the clearest premium opportunity without abandoning the established PEG 3350 powder platform.

References

1. DailyMed. (n.d.). ClearLax polyethylene glycol 3350 powder, for solution: Drug facts label. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Laxative drug products for over-the-counter human use. Code of Federal Regulations and OTC drug monograph materials.
3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Polyethylene glycol 3350 monograph. USP-NF.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.